Interview with transkript & EBM: "Ready to set sail to the clinic"
We are happy to share a follow-up interview about Indivumed's repositioning from a service-based business into a biotech company.
:format(webp))
Interview with transkript & EBM
"Jetzt einsteigen, Leinen los!" - Indivumed is ready to set sail to the clinic.
In a follow-up interview published in transkript magazine and European Biotechnology Magazine (EBM), our CEO, Prof. Dr. Hartmut Juhl , and our CBO, Dr. Matthias Evers, discuss with journalist Dr. Georg Kääb how Indivumed has fully separated from its biobank service business and repositioned itself as a therapeutics biotech with its own drug development pipeline.
Both Hartmut and Matthias emphasize our progress: "We have built a comprehensive universe of targets and prioritized around 25 targets in colorectal cancer alone. While completing an antibody triage system based on organoid models, we also made significant advances in small molecules".
With a strong technological foundation and a clear strategic focus, Indivumed is increasingly being recognized as a highly innovative biotech company with its own pipeline, and we are now actively seeking partners to accelerate development.
We are pleased to share the interview, published in the German transkript magazine by knowbio and also featured online in English on European Biotechnology Magazine.